7/8 High-Resolution Unrelated Donor HLA Match Rate: Caucasian, African American, Hispanic, and Asian-Pacific Islander

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 1998-1998
Author(s):  
Kelly Buck ◽  
Jason Dehn ◽  
Michelle Setterholm ◽  
Martin Maiers ◽  
Dennis L. Confer ◽  
...  

Abstract Aim Estimation of the National Marrow Donor Program's Be The Match Registry (BTMR) 8/8 (HLA-A, B, C, DRB1) high resolution (HR) unrelated donor (URD) match rate was determined in a 2009 study for each of the four most frequent patient race/ethnic groups in the United States- Caucasian (CAU), African American (AFA), Hispanic (HIS), and Asian Pacific Islander (API) (Dehn et al, ASBMT/CIBMTR abstract 2011). For patients without an 8/8 matched URD, a 7/8 match is often the minimum acceptable mismatch used by many transplant centers. A follow up to the 8/8 study was designed to determine the 7/8 or better match rate among the 4 major race/ethnic groups, using the same study cohort. Methods 1344 previously high resolution tested URD in the BTMR were randomly selected and treated as pseudopatients (PP) where HR testing was performed to identify an 8/8 matched URD. Following 8/8 potential URD testing, a search was performed on each PP to determine the 7/8 match rate, regardless of whether an 8/8 match was previously identified. The searches used a fixed BTMR file from January of 2012, composed of over 8.6 million URD. The BTMR race/ethnic diversity breakdown for 2012 was 65% CAU, 7% AFA, 10% HIS, 7% API, and 11% miscellaneous categories such as Multiple, Unknown, American Indian- Alaska Native, and Declined to answer. Search results from CAU (N=377), AFA (N=390), HIS (N=307), and API (N=270) PP were evaluated and classified as follow: 1) 7/8 HR matched donor exists on BTMR 2) Potential 7/8 HR donors exist on BTMR 3) No 7/8 potential donors exist on BTMR PP searches falling into category 2 had an HLA search strategy expert rank potential URD within BTMR in order of their matching likelihood. URD samples were HR HLA tested in order of ranking and evaluated to determine match status. Consecutive rounds of URD sample testing were performed until either a 7/8 matched URD was identified, no potential URD with stored samples remained, or a patient maximum number of URD testing was reached. Since many PP searches had greater than 100 potential 7/8 matched URD, it was not possible to type every URD. In these cases, up to 35 URD with sample were tested per patient. For analysis of the 7/8 match rate, PP with no 7/8 match identified after URD testing were considered as having no HR match. Results 98% of CAU and over 80% of the non-CAU race/ethnic groups- AFA, HIS, and API- had at least a 7/8 match identified (Table 1). For cases where an 8/8 matched donor had been previously identified, all but 8 PP also had a 7/8 match (CAU= 1, AFA= 3, API= 3, HIS= 1). Only three PP cases had no 7/8 potential donors on the search prior to URD testing. The range of donors tested for the cases resulting in a match was larger for the non-CAU race groups. The maximum number of URD tested before a 7/8 match was identified was 24 for AFA, 6 for HIS, and 10 for API, while for CAU the maximum number of URD tested was 2 (Table 2). A median of 1 URD was typed for cases resulting in a 7/8 match for each of the four race/ethnic groups. HLA expert review of cases where no 7/8 match was identified but additional 7/8 potential URD remained suggests that few additional cases would likely yield HR matches. Conclusions This study estimates a 7/8 or better HR match rate for the BTMR of over 80% for all four broad race/ethnic group categories. These results show that in the majority of cases, after first testing to identify an 8/8 matched URD, a 7/8 matched URD was identified after typing just one URD. However, particularly with non-CAU patients, testing additional URD may be needed to identify a 7/8 match. This study provides a baseline match rate that can be further supplemented using the additional worldwide URD inventory. Disclosures: No relevant conflicts of interest to declare.

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 681-681
Author(s):  
Rita Choula

Abstract Caregiving in the U.S. 2020 oversampled African Americans, Hispanics, Asians, and people over the age of 75. Six in ten caregivers report being non-Hispanic white, 17% are Hispanic, 14% non-Hispanic African-American or black, 5% Asian/Pacific Islander, and 3% some other race or ethnicity, including multiracial. The session will emphasize the unique context of diverse caregivers, including African American, Hispanic, Asian, and LGBT+ caregivers. The session will begin by discussing the portrait of the typical caregiver of each of these groups. It will follow with a discussion of the challenges facing diverse caregivers in the aggregate and the opportunities to recognize and support them across settings.


2021 ◽  
Vol 23 (Supplement_1) ◽  
pp. i16-i17
Author(s):  
Nayan Lamba ◽  
Bryan Iorgulescu

Abstract Introduction Primary intracranial germ cell tumors (GCTs) appear to be more prevalent among pediatric patients in eastern Asia than in the U.S. Herein we use cancer registry data to evaluate whether GCT prevalence differs by race/ethnicity among U.S. pediatric patients. Methods Pediatric patients (age≤14) presenting between 2004–2017 with a primary intracranial GCT were identified by ICD-O-3 histological and topographical coding from the National Cancer Database (comprising >70% of cancers newly-diagnosed cancers in the U.S.), and categorized by NICHD age stages. Patients’ age, sex, race/ethnicity, and overall survival, and tumor location and size were evaluated. Results 889 pediatric patients with primary intracranial GCTs were identified, which were overwhelmingly male (64.8%) and pure germinomas (64.0%). Non-germinomatous (24.5%) and mixed (11.5%) tumor types were in the minority. Overall, primary GCTs comprised 4.9% of intracranial tumors in pediatric males and 2.9% of intracranial tumors in pediatric females. Asian/Pacific Islander pediatric patients in the U.S. had a notably higher prevalence of GCTs: among Asian/Pacific Islander males, 10.6% of all brain tumors were GCTs, compared to only 4.5% in White non-Hispanic patients, 2.8% in Black non-Hispanic patients, and 6.0% in Hispanic patients. Despite the much lower prevalence of GCTs among female patients overall, this predominance also persisted for Asian/Pacific Islander females, among whom 7.5% of brain tumors were GCTs, compared to only 2.5% in White non-Hispanic patients, 2.4% in Black non-Hispanic patients, and 4.1% in Hispanic patients. Overall, 9.4% of pediatric primary intracranial GCTs occurred in patients of Asian/Pacific Islander race/ethnicity, in contrast to 4.0% of diffuse astrocytic/oligodendroglial tumors, 2.8% of other astrocytic tumors, or 4.6% of embryonal tumors. Conclusions Primary intracranial GCTs affect a substantially larger proportion of both male and female pediatric patients of Asian/Pacific Islander race/ethnicity in the United States.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17583-e17583
Author(s):  
Marcus Kyle Weldon ◽  
Takefumi Komiya ◽  
Achuta Kumar Guddati

e17583 Background: Squamous cell carcinoma is the most common subtype of malignancy found in patients with Head and Neck malignancy. There are other rare subtypes which are not adequately reported in medical literature. Lymphoepithelial carcinoma consists of lymphocytic infiltration in a background of undifferentiated carcinoma cells and has a high malignant potential. They are most often seen in salivary glands but can also be found in other structures of the head and neck region. This analysis reports the nation-wide mortality of patients diagnosed with lymphoepithelial carcinoma of the Head and Neck. Methods: Data was extracted from the Surveillance, Epidemiology, and End Results (SEER) Database from the years 2000 to 2014. Incidence-based mortality for all stages was queried and results were grouped by gender and race (Caucasian/White, African American/Black, American Indian/Alaskan native and Asian/Pacific Islander). Paired T-test was used to determine statistically significance difference between various subgroups. Results: Incidence-based mortality has been improving for African American/Black patients and has been worsening for Caucasian/White, American Indian/Alaskan native and Asian/Pacific Islander for the period of 2000 to 2014. The differences in mortality trends were statistically different (P < 0.05). The highest mortality rate per 1000 patients was seen in Asian/Pacific Islander population, followed by African American/Black, American Indian/Alaskan native and the least mortality was noted in Caucasian/White patients. When a similar analysis with linearized trend lines on gender was conducted, only African American/Black males and Asian/Pacific Islander females showed an improving trend in mortality. The sample size was a major limitation of this study (Caucasian/White - 134, African American/Black - 30, American Indian/Alaskan native - 5 and Asian/Pacific Islander – 87). Conclusions: Lymphoepithelial carcinoma is a rare subtype of Head and Neck malignancies whose incidence-based mortality showed a worsening trend. This study showed significant race and gender disparity amongst patients with lymphoepithelial carcinoma. Due to its rarity, this subtype warrants further study; especially with regards to its etiology, clinical course and cure rates.


2010 ◽  
Vol 107 (3) ◽  
pp. 972-976 ◽  
Author(s):  
Pamela C. Regan ◽  
Carlos Anguiano

This study examined the association between romanticism (operationalized as mean score on the Romantic Beliefs Scale) and age, sex, and ethnicity in a large community sample ( N = 436). Age was negatively correlated with romanticism scores; as age increased, romanticism scores decreased. No sex differences were found; men and women had similar, moderate scores. Although ethnicity largely was unrelated to romanticism, Asian/Pacific Islander participants were significantly more romantic than were African-American participants.


2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e21061-e21061
Author(s):  
William Forehand ◽  
Swathi Gopishetty ◽  
Ashkan Shahbandi ◽  
Achuta Kumar Guddati

e21061 Background: Ocular and orbit melanoma is a rare subtype of melanoma for which outcomes have not been adequately reported. In this study we he have analyzed the incidence-based mortality trends of ocular and orbit melanoma over a 15 year period. Most ocular melanomas originate from the uvea and to a lesser extent from the conjunctiva. Primary orbital melanoma is exceedingly rare. The incidence of ocular melanoma has been stable for the past few decades but incidence-based mortality has not been studied over the past 15 years. Methods: The Surveillance, Epidemiology, and End Results (SEER) Database was utilized to query the incidence-based mortality for all patients diagnosed with ocular and orbit melanoma for the years 2000 to 2014. The results were grouped by gender and race (Caucasian/White, African American/Black, American Indian/Alaskan native and Asian/Pacific Islander). Paired T-test was used to determine statistically significance difference between various subgroups (p < 0.05). Results: Incidence-based mortality has been the highest in Caucasian/White patients from 2000 to 2014 followed by African American/Black and Asian/Pacific Islander patients. American Indian/Alaskan native patients appear to have the least mortality. There was a statistically significant difference (p < 0.05) in mortality between Caucasian/White patients from 2000 to 2014 followed by African American/Black and Asian/Pacific Islander patients. The sample size for African American/Black and American Indian/Alaskan native patients was too low for discerning a meaningful trend in mortality. Overall it appears that Caucasian males and females have a far higher and worsening incidence-based mortality compared to other races. Conclusions: Ocular melanoma and orbit melanoma are rare entities which are predominantly seen in Caucasian/White patients. This study shows that the incidence-based-mortality has been worsening for these patients in the past two decades. These entities have poor prognosis and have not been studied extensively in immunotherapy trials. This study highlights the need for new clinical trials to help improve the mortality rates.


Sign in / Sign up

Export Citation Format

Share Document